Clinical trial · Interventional
Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years
A Multicenter，Open-label，Radonmized Study on the Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years Old
NCT02432872CI-TRIAL-00024172unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the escalation dosage of Daunorubicin and cytarabine is effective and safety in the treatment of older adult Chinese acute myeloid leukemia（AML） patients aged 55 to 65 years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cytarabine | Drug | Cytarabine | ALIAS |
| Daunorubicin | Drug | Daunorubicin | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- escalated daunorubicin
- description
- Daumorubicin 60mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
- interventionNames
- Drug: Daunorubicin
- Drug: Cytarabine
- type
- ACTIVE_COMPARATOR
- label
- standard daunorubicin
- description
- Daunorubicin 45mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
- interventionNames
- Drug: Daunorubicin
- Drug: Cytarabine
- type
- EXPERIMENTAL
- label
- medium dosage cytarabine
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 55 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * primary AML（except APL patients）; * ECOG PS:0-2 Exclusion Criteria: * AML patient who has already received induction treatment, no matter what the outcome is; * Treatment-related AML; * Active cancer patients who's condition need to be treated; * The one with serious infectious diseases（eg.uncontrolled tuberculosis or invasive pulmonary aspergillosis） * Active heart disease.
References
Publications (1)
- DERIVEDZhou C, Li L, Li Y, Liu K, Liu Y, Lin D, Gong B, Zhang G, Gong X, Fang Q, Liu B, Qiu S, Wang Y, Wei H, Mi Y, Wang J. Daunorubicin-45 Vs. Daunorubicin-60 for Induction in Intermediate-Age Patients of AML: Results From a Randomized Trial. Cancer Sci. 2026 Jun;117(6):1690-1700. doi: 10.1111/cas.70383. Epub 2026 Apr 15. PMID 41986965